Ultragenyx Pharmaceutical Inc (RARE)
42.61
+1.49
(+3.62%)
USD |
NASDAQ |
May 16, 16:00
42.60
-0.01
(-0.02%)
Pre-Market: 20:00
Ultragenyx Pharmaceutical Cash from Operations (Quarterly): -190.73M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -190.73M |
| December 31, 2023 | -83.90M |
| September 30, 2023 | -117.87M |
| June 30, 2023 | -116.16M |
| March 31, 2023 | -156.87M |
| December 31, 2022 | -90.34M |
| September 30, 2022 | -95.34M |
| June 30, 2022 | -77.26M |
| March 31, 2022 | -117.52M |
| December 31, 2021 | -54.34M |
| September 30, 2021 | -59.65M |
| June 30, 2021 | -65.36M |
| March 31, 2021 | -159.35M |
| December 31, 2020 | -62.45M |
| September 30, 2020 | -61.97M |
| June 30, 2020 | 87.35M |
| March 31, 2020 | -95.15M |
| December 31, 2019 | -72.04M |
| September 30, 2019 | -88.51M |
| June 30, 2019 | -89.06M |
| March 31, 2019 | -95.78M |
| December 31, 2018 | -55.85M |
| September 30, 2018 | -69.16M |
| Date | Value |
|---|---|
| June 30, 2018 | -76.08M |
| March 31, 2018 | -89.48M |
| December 31, 2017 | -81.82M |
| September 30, 2017 | -61.99M |
| June 30, 2017 | -48.82M |
| March 31, 2017 | -61.20M |
| December 31, 2016 | -47.68M |
| September 30, 2016 | -28.74M |
| June 30, 2016 | -39.66M |
| March 31, 2016 | -44.90M |
| December 31, 2015 | -40.44M |
| September 30, 2015 | -30.60M |
| June 30, 2015 | -17.27M |
| March 31, 2015 | -17.66M |
| December 31, 2014 | -12.45M |
| September 30, 2014 | -11.03M |
| June 30, 2014 | -10.53M |
| March 31, 2014 | -10.62M |
| December 31, 2013 | -9.773M |
| September 30, 2013 | -6.747M |
| June 30, 2013 | -8.387M |
| March 31, 2013 | -6.293M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-190.73M
Minimum
Mar 2024
87.35M
Maximum
Jun 2020
-88.33M
Average
-88.78M
Median
Cash from Operations (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 23.76M |
| Madrigal Pharmaceuticals Inc | -149.16M |
| Sarepta Therapeutics Inc | -242.08M |
| FibroGen Inc | -59.29M |
| Rocket Pharmaceuticals Inc | -56.86M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 94.44M |
| Cash from Financing (Quarterly) | -0.058M |
| Free Cash Flow | -543.61M |
| Free Cash Flow Per Share (Quarterly) | -2.420 |
| Free Cash Flow to Equity (Quarterly) | -203.94M |
| Free Cash Flow to Firm (Quarterly) | -196.90M |
| Free Cash Flow Yield | -16.57% |